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Objective: To explore the effects of arteannuin B, arteannuic acid and scopoletin on the
pharmacokinetics of artemisinin in mice.
Methods: Artemisinin and a combination of artemisinin, arteannuin B, arteannuic acid
and scopoletin were administered together to mice via oral administration. Blood samples
were collected at different time intervals and pretreated by liquid–liquid extraction. The
contents of four compounds in mouse plasma were determined by a validated HPLC-MS/
MS method.
Results: Compared to single artemisinin group, the Cmax values from the combination
group rose from 947 ng/mL to 1254 ng/mL. AUC(0-t) (2371 h ng/mL) was signiﬁcantly
higher than that from single artemisinin group (747 h ng/mL). The peak time lag and the
CL values reduced at a proportion of 66%.
Conclutions: Arteannuin B, arteannuic acid and scopoletin can markedly affect the
pharmacokinetics of artemisinin.EDITOR'S NOTE
This research project of article is conducted by the Nobel Laureate Professor Youyou Tu's ﬁrst Ph.D student, Associate Professor
Man-Yuan Wang together with his student. Their three generations have been studying on artemisinin and made great achievements,
signiﬁcantly contributing to defeating malaria.1. Introduction
Artemisinin-based drugs are now the ﬁrst line drugs for
malaria treatment. Since 2001, WHO has recommended com-
bination therapies of artemisinin-based combination therapies
(ACTs) [1–3] to treat malaria in order to avoid drug resistance.
Generally, combination therapies of shorter half-life artemisi-
nin-based drugs with longer half-life ones can avoid the emer-
gence of low plasma concentration and delay development of
drug resistance due to different anti-malarial mechanism [4,5].
However, the current ACTs almost refer to artemisinins in
combination with amino-quinoline drugs [6]. WHO pointed out
in 2005 that people may seriously face reduced susceptibility
of anti-malarial drugs, and warned likely occurrence of drugresistance in the relevant reports. Emergence of drug resistance
of Plasmodium falciparum to artemisinins has been conﬁrmed at
border areas of Cambodia and Thailand in 2009. The same sit-
uation was found in Myanmar and Vietnam later. Once malaria
parasites were resistant to current ACTs in a wide range, it
would lead to a difﬁcult situation of no cure for malaria. Com-
plex life cycle of Plasmodium objectively increase the difﬁculty
of vaccine development. So far, there is still no effective vaccine
for malaria prophylaxis. According to World Malaria Report in
2015 from WHO [7], about 3.2 billion people worldwide were
faced with the risk of malaria. In 2015, there were still about
214 million new cases of malaria, with 438000 deaths. It
would be a disaster without effective anti-malarial drugs to
achieve global malaria control goal. Therefore, research of
looking for new anti-malarial drugs has practically been an
urgency.
In 1970s, research team led by Youyou Tu discovered that
the effectiveness of traditional Chinese medicine Aretemisia
annua L. (A. annua) to treat malaria is a result of artemisinin-
based multicomponent interaction. We conducted multicom-
ponent compatibility test of anti-malaria effectiveness in our
early studies, and found antimalarial activity of artemisinin is
signiﬁcantly improved when combination of arteannuin B,
arteannuic acid and scopoletin extracted from A. annua wasrticle under the CC BY-NC-ND license (http://
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signiﬁcant antimalarial activity was not observed when
arteannuin B, arteannuic acid and scopoletin neither alone or
combined. Experiments conﬁrmed that combination use of
artemisinin, arteannuin B, arteannuic acid and scopoletin in a
mass ratio of 1:1:1:1 showed better Plasmodium inhibition in
malaria mouse model, achieving the same anti-malarial effect
of four times dose of artemisinin. This study aims to further
explore synergistic mechanism of artemisinin, arteannuin B,
arteannuic acid and scopoletin on malaria mouse model which
is considered more convenient and reliable generally than other
model. Studies of single artemisinin therapy and four-
component combination therapy on malaria mouse model
were carried out to explore the their pharmacokinetic charac-
teristics, especially to explore the potential interaction and rules
of arteannuin B, arteannuic acid and scopoletin on artemisinin
so that mechanism of four components combination can be
further explained, and the foundation for further development
of new ACTs can be laid.
2. Experimental and methods
2.1. Chemicals and reagents
Artemisinin, arteannuin B and arteannuic acid (purities
>98.4%) were provided by our laboratory. Scopoletin (purity of
98%) was purchased from Beijing Lark Technology Co., Ltd.
(Beijing, China). Buspirone (purity of 99.3%) was purchased
from Sigma Co., Ltd. (St. Louis, Mo, USA). Methanol and
acetonitrile were HPLC grade and purchased from Fisher
(Massachusetts, USA). Formic acid (analytical grade) was
purchased from Beijing Yili Fine Chemicals Co., Ltd. (Beijing,
China). Methyl tert-butyl ether (analytical grade) was pur-
chased from Tianjin Fuchen Chemical Reagent (Tianjin,
China). Sodium carboxymethylcellulose was purchased from
Beijing Fengli Jingqiu Commerce and Trade Co., Ltd. (Beijing,
China).
2.2. Animal
ICR mice were obtained from Beijing Vitalriver Experi-
mental Animal Technical Co., Ltd. (Beijing, China). Ninety-six
male mice (20 ± 2) g were kept in an environmentally controlled
breeding room for one week before starting the experiments and
fed with standard laboratory food and water. They were
randomly divided into sixteen groups (six animals per group)
and were fasted overnight with free access to water before
administration.
2.3. LC–MS/MS instruments and conditions
The liquid chromatography (LC) was performed on an Agi-
lent 1200 series LC (Agilent Technologies, Palo, Alto, CA,
USA), which included an Agilent 1200 binary pump (model
G1316B), vacuum degasser (model G1322A), Agilent 1200
autosampler (model G1367C), and temperature controlled col-
umn compartment (model G1330B). Chromatographic separa-
tion was carried on an Agilent Zorbax XDB-C18 analytical
column (50 mm × 2.1 mm, 3.5 mm, Agilent Technologies, Santa
Clara, CA, USA) maintained at 30 C. The mobile phase was
consisted of 0.1% formic acid solution (A) and acetonitrile (B).The solvent gradient was as follows: 0–1 min with 5% B, 1–
1.1 min with 5%–10% B, 1.1–5 min with 10%–95% B, 5–6 min
with 95% B, 6–6.1 min with 95%–5% B and 6.1–10 min with
5% B. The ﬂow rate was 0.3 mL/min and the injection volume
was 10 mL.
The LC system was coupled to an Agilent 6410 triple
quadrupole mass spectrometer (USA) equipped with an ESI
source. The mass spectrometer was operated in the positive
(artemisinin, arteannuin B and scopoletin) and negative
(arteannuic acid) ESI mode with the drying gas temperature of
300 C with N2 gas ﬂow at 10 L/min, nebulizer pressure of
30 psi, and capillary voltage of 4000 V. The multiple reaction
monitoring (MRM) transitions were chosen to be m/z
283.2 / 247.1 for artemisinin, m/z 249.1 / 189.1 for
arteannuin B, m/z 232.8 / 232.8 for arteannuic acid, m/z
193.0 / 133.0 for scopoletin and m/z 386.3 / 122.1 for
buspirone. The fragmentor voltage values set for artemisinin,
arteannuin B, arteannuic acid, scopoletin and buspirone were
100 V, 120 V, 130 V, 120 V and 100 V, respectively. The
collision energies were set to be 9 eV, 10 eV, 3 eV, 25 eV and
40 eV, respectively.
2.4. Design of pharmacokinetic experiments
Ninety-six animals were divided into two groups. The group
of single artemisinin mice (n = 48) were orally administered
with artemisinin of 100 mg/kg; while the mice of the combi-
nation group (n = 48), were orally administered with a dosage
of 100 mg/kg of artemisinin, arteannuin B, arteannuic acid and
scopoletin. Each group was randomly divided into 8 groups
corresponding to a total number of 8 sampling points at 0.08,
0.25, 0.5, 1, 2, 5, 8, 12 h after dosing and each sampling points
has 6 mice. Aliquots of 300 mL of blood was collected into
heparinized syringes from eyeball of mice under anesthesia at
0.08, 0.25, 0.5, 1, 2, 5, 8, 12 h after oral administration. Blood
samples were centrifuged at 3000 r/min for 10 min. Then, all
the plasma samples were stored at −80 C until analysis.
2.5. Plasma sample preparation
All samples were stored in a freezer at −80 C and allowed to
thaw at room temperature before processing. An aliquot of
50 mL mouse plasma was mixed with 10 mL 20% methanol
aqueous solution, 10 mL buspirone solution (100 ng/mL) and
10 mL 0.1% formic acid solution. Then, 400 mL of the extraction
solution, methyl tert-butyl ether, was added. After mixing in
automatic shakers for 1 min, samples were submitted to centri-
fugation at 3500 r/min for 10 min. Then, 300 mL of the super-
natant were transferred to a clean tube and evaporated under
nitrogen ﬂow. The residue was reconstituted in 100 mL 50%
acetonitrile aqueous solution and vortexed for 1 min. Then ali-
quots of 10 mL solution were injected into the HPLC–MS/MS
system for analysis.
2.6. Pharmacokinetic calculation and statistical analysis
The pharmacokinetic parameters including Cmax, Tmax, AUC,
and t1/2 etc., were calculated by noncompartmental analysis, us-
ing pharmacokinetic analysis package Winnonlin software. Sta-
tistical analyses were performed using SPSS software version.
P < 0.05 was considered statistically signiﬁcant difference.
Table 1
Correlation coefﬁcient, linear range and LLOQ of artemisinin, arteannuin B, arteannuic acid and scopoletin in mice plasma tested by LC-MS/MS.
Analyte Calibration curves Correlation coefﬁcient (R) Range (ng/mL) LLOQ (ng/mL)
Artemisinin y = 0.002 070x + 0.001 960 0.999 2.00–1000.00 2.00
Arteannuin B y = 0.006 370x + 0.008 780 0.998 2.00–1000.00 2.00
Arteannuic acid y = 0.000 139x + 0.001 180 0.995 2.00–1000.00 2.00
Scopoletin y = 0.004 620x + 0.006 530 0.999 2.00–1000.00 2.00
Figure 1. Mean plasma concentration–time curve of artemisinin in mouse plasma after oral administration of single artemisinin or the combination of
artemisinin, arteannuin B, arteannuic acid and scopoletin (n = 6). Compared with normal single artemisinin, △P > 0.05; **P < 0.01.
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3.1. Assay validation
The blank plasma sample spiked with standard and a plasma
sample from a mouse after an oral administration of drugs were
tested. All samples were found to have no interference from
endogenous substances affecting the retention times of artemi-
sinin, arteannuin B, arteannuic acid, scopoletin and buspirone.
No cross-talk peaks were observed among the analytes. The run
time of each sample was 10.00 min, and the respective retention
times of artemisinin, arteannuin B, arteannuic acid, scopoletin
and buspirone were 6.91 min, 6.68 min, 7.59 min, 5.20 min and
5.32 min. The calibration curves were linear over the concen-
tration ranges of 2–1000 ng/mL in mouse plasma with good
reproducibility and linearity. It was assessed by analyzing the
calibration curves using the peak area ratios of analyte/buspironeTable 2
Main Pharmacokinetic parameters of single artemisinin, arteannuin B, artean
combination of artemisininn (n = 6).
PK Parameters Unit Single Combinati
AUC(0-t) h$ng/mL 747.00 2371.0
AUC(0-∞) h$ng/mL 793.00 2396.0
Cmax ng/mL 947.00 1254.0
Tmax h 0.25 0.5
MRT(0-t) h 0.93 1.8
MRT(0-∞) h 2.55 1.9
t1/2 h 11.50 1.8
Ke 1/h 0.06 0.3
Vd mL/kg 2099106.00 109228.0
CL mL/h/kg 126111.00 41732.0versus the nominal concentrations of the analyte calibration
standard with a weighting factor (1/x2). Obtained correlation
coefﬁcients (r) were higher than 0.99, indicating that all cali-
bration curves met the acceptance criteria (Table 1).
Precision and accuracy of the developed method were vali-
dated by assaying the QC samples at three concentration levels
in plasma. In this assay, the intra- and inter-day precisions were
measured to be below 8.55% and 9.20%, respectively. These
values were within the acceptable range, and the method was
thus judged to be suitably accurate and precise. The stability of
the analytes during the sample preparation procedures and
storage was evaluated by analysis of three levels of QC samples.
The results indicated the stability of artemisinin, arteannuin B,
arteannuic acid and scopoletin in plasma after storage at room
temperature for 24 h, at −80 C for 30 d and after three freeze–
thaw cycles at −20 C. The results indicated that four compo-
nents were stable under different storage conditions. Thenuic acid and scopoletin in mice plasma after oral administration of the
on Arteannuin B Arteannuic acid Scopoletin
0 461.00 550477.00 1242.00
0 477.00 556782.00 1452.00
0 278.00 195570.00 716.00
0 0.25 0.50 0.25
4 2.46 2.12 2.82
8 2.93 2.26 5.50
1 2.84 1.74 6.49
8 0.24 0.40 0.11
0 859 071.00 450.00 645168.00
0 209 636.00 180.00 68871.00
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demonstrate that there was no concentration bias. The mean
recovery was 89.5%–99.3% for artemisinin, 86.9%–99.0% for
arteannuin B, 93.4%–99.3% for arteannuic acid and 85.2%–
91.6% for scopoletin. These available data demonstrated that the
proposed method was accurate, reliable and reproducible for the
quantitation of artemisinin, arteannuin B, arteannuic acid and
scopoletin in mouse plasma.
3.2. Pharmacokinetic study
The validated LC–MS/MS method was successfully applied
to the pharmacokinetic study of artemisinin, arteannuin B,
arteannuic acid and scopoletin in mice after an oral administra-
tion. The mean plasma concentration–time curves of artemisinin
in mouse plasma after oral administration of single artemisinin or
the combination of artemisininn are shown in Figure 1 and main
pharmacokinetic parameters are presented in Table 2. The main
pharmacokinetic parameters of arteannuin B, arteannuic acid and
scopoletin in mouse plasma after oral administration of the
combination of artemisinin are presented in Table 2.
4. Discussion
During LC–MS/MS assay development, the sensitivity,
selectivity and robustness of the assay had been taken into the
consideration. Artemisinin is sesquiterpene lactones containing
peroxide bridges, missing from the molecular structure of the
conjugated system; using conventional UV detector is difﬁcult
to achieve the purpose of the quantitative analysis of biological
samples. The experiment used liquid chromatography tandem
mass spectrometry (LC-MS/MS) to establish artemisinin,
arteannuin B, arteannuic acid and scopoletin determination of
drug concentration in mouse plasma. In order to improve the
accuracy of the method and reduce the experimental error,
buspirone was selected as an internal standard, to avoid the er-
rors caused in sample handling and injection process. The
negative ion mode and the positive ion mode were tested, the
test results showed that response intensity obtained was high of
arteannuic acid by negative ion mode, but other three compo-
nents adapted to be detected in positive ion mode. At the same
time, the test results also showed that given a large collision
energy, arteannuic acid precursor ion all became fragmented,
and there was no characteristic ions, while a smaller energy
collision was used, there was only the parent ion, and no frag-
ment ions, so ﬁnal collision with a smaller energy only detect the
parent ion concentration.
An efﬁcient method for bio-sample cleanup to remove pro-
tein and potential interference from endogenous substances prior
to LC–MS/MS analysis is important in the method development.
At present, the common biological sample preparation includes
protein precipitation (PPT), solid-phase extraction (SPE) and
liquid–liquid extractions (LLE). Because of using SPE need high
cost, in our study, different extraction procedures like PPT and
LLE were tested. The test results showed that artemisinin was
not detected with PPT, however, four components could be
detected by liquid–liquid extraction method. Based on this, two
kinds of organic solvents, methyl tert-butyl ether and dichloro-
methane with different volumes were tested as the LLE solvent
in order to obtain higher extraction recovery. The test results
showed that the recovery of dichloromethane was lower thanmethyl tert-butyl ether. Finally, LLE with eight volumes of
methyl tert-butyl ether was adopted for sample preparation. The
supernatant after centrifugation was dried using nitrogen prior to
the LC–MS/MS assay for enhancing the sensitivity.
Artemisinin can be absorbed quickly after oral administra-
tion, the Tmax (time to reach maximum plasma concentration) is
1–2 h in blood. But it cannot be completely absorbed and the
bioavailability is low [10]. The radioactivity in mouse blood
rapid rose after oral administration of 3H- artemisinin, the
Tmax was 1 h, then plasma concentrations of artemisinin
declined rapidly with terminal elimination half-life (t1/2) was
4 h [11]. Weathers et al. [12] investigated and found the Tmax was
1 h and the Cmax (the maximum plasma concentration) was
74 ng/mL in mouse plasma after oral administration of 70 mg/
kg dose of artemisinin; at the same time, Tmax was much more
short after oral administration the leaves of A. annua. In the
study, the artemisinin was rapidly absorbed by mice with
0.25 h to reach Cmax of 947 ng/mL after oral administration
artemisinin (100 mg/kg).
Melillo de Magalhaes et al. [13] reported rosemary acid and
chlorogenic acid can increase bioavailability of artemisinin by
inhibiting the activity of CYP3A4 and CYP1A1. Compared
with the oral administration of single artemisinin, the Cmax of
the artemisinin after the oral administration of the combination
of artemisinin was signiﬁcantly increased from 947 ng/mL to
1254 ng/mL and area under the plasma concentration–time
curve (AUC) from time 0–12 h (AUC0-12) of artemisininn was
signiﬁcantly increased by 3.17 times in combination group.
The reasons for these results, on the one hand, may be due to
the enzymatic interaction of arteannuin B, arteannuic acid and
scopoletin with artemisinin, which can inhibit the metabolic
enzymes. On the other hand, three components may affect the
binding of artemisinin with serum albumin, and then the
protein storage and transport of artemisinin in vivo was
changed. Preliminary studies showed that the quenching
constant and binding constants of artemisinin with bovine
serum albumin in four-components combination group were
increased, compared to the single artemisinin group, which can
affect the pharmacokinetic behavior of artemisinin [14].
Since ACTs was considered as ﬁrst-line antimalarial drugs
recommended by WHO, in Africa and other places, the general
public is difﬁcult to accept such a high price of drugs and the
clinical use of these drugs were hindered. On the other hand,
although there are no clear clinical teratogenic and mutagenic
effect reports of artemisinin-based drugs, some patients during
pregnancy fear the toxicity rather than treatment of malaria using
ACTs, because it has been observed that artemisinin-based drugs
can lead to fetal resorption toxicity in animal models of rats and
rabbits. These factors lead to the application of the herb
A. annua for treating malaria being more common in some parts
of Africa [15]. The research team of Youyou Tu has conﬁrmed
the acidic parts of ether extract has strong toxicity [16]. At the
same time, the WHO made it clear that due to the fear that the
use of the herbal medicine of A. annua for treating malaria
patients is difﬁcult to ensure adequate therapeutic drug plasma
concentration, malaria parasites cannot be killed effectively
and the patients received a dose of artemisinin insufﬁcient to
eliminate the parasites. Considering such sub-curative doses
could promote the emergence of Plasmodium resistance to
artemisinins, the herb A. annua is not recommended to treat
malaria [17].
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anti-malarial drugs, some foreign researchers has developed and
paid more attention to the artemisinin-based natural components
in A. annua. De Donnoa et al. [18] found that the antimalarial
activity of A. annua tea is higher than puriﬁed artemisinin.
Suberu et al. [19] found artemisinic acid and arteannuin B
showed additive interaction while rosmarinic acid showed
synergistic interaction with artemisinin in the chloroquine
sensitive strain; in the chloroquine resistant parasite,
arteannuin B was synergistic. Elfawal et al. [20] found that a
single dose of the dried leaves of whole plant A. annua
(pACT) (containing 24 mg/kg artemisinin) reduces parasites
more effectively than a comparable dose of puriﬁed
artemisinin. The bioavailability of artemisinin in the blood of
mice fed the pACT increased 40-fold. The above results
suggest that A. annua can be developed into the possibility of
multicomponent plant antimalarial agents. Elfawal et al. [21]
showed that pACT overcomes existing resistance to pure
artemisinin in the rodent malaria infected by Plasmodium
yoelii, with the ability to reverse the drug resistance of
Plasmodium. The pACT has the potential for further
development of nonpharmaceutical forms to treat human
malaria.
This study suggests the pharmacokinetics of artemisinin can
be changed by other components in A. annua to enhance the
antimalarial effect. Further studies about the optimal ratio and
synergistic mechanism of the multi-components combination
therapies from A. annua are very signiﬁcant for the development
of new ACTs and new antimalarial strategies.
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